Inspire Medical Investors Face Jan. 5 Deadline in Lawsuits Over Troubled Inspire V Rollout

Plaintiffs say Inspire misled investors about Inspire V launch readiness, citing an 80% guidance cut that coincided with a steep August 4 stock plunge.

Overview

Multiple investor-rights firms, including Rosen, Schall, Gross, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Gainey McKenna & Egleston, and the Law Offices of Frank R. Cruz, are urging INSP shareholders to seek lead-plaintiff status by January 5, 2026.
The actions target purchases made between August 6, 2024 and August 4, 2025, the period identified as the class window in the filed complaints and notices.
The complaints allege Inspire overstated demand and operational readiness for the Inspire V device, asserting providers held surplus inventory and were slow to transition.
Operational gaps cited include incomplete training and onboarding at treatment centers, missing IT and customer-approval processes, insurer claims software not updated, and challenges adopting Medicare CPT code 64568.
The litigation is pending in the U.S. District Court for the District of Minnesota, no class has been certified, and notices emphasize that investors can share in any recovery without serving as lead plaintiff.